Early experiences with two transcatheter mitral valve implantation (TMVI) devices—Intrepid (Medtronic) and the Tendyne mitral valve (Abbott)—indicate that TMVI may be a safe and effective approach for managing mitral regurgitation in patients at high risk for surgical complications. However, further studies are needed to support these findings.
David Cohen (Saint Luke’s Mid America Heart Institute, Kansas City, USA) has suggested that, on basis of both clinical and economic considerations, transcatheter aortic valve implantation (TAVI) should be the first-line approach for patients with aortic stenosis at intermediate risk. He noted that data from the PARTNER 2A and Sapien 3 trials indicate that TAVI in intermediate-risk patients results in cost savings and greater quality adjusted life expectancy.
New clinical research, presented today at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October- 2 November, Denver, USA), support the positive clinical performance of the Evolut transcatheter aortic valve implantation (TAVI) device (Medtronic) in aortic stenosis patients at intermediate risk. The data were from the SURTAVI (Surgical replacement and TAVI) trial and the Evolut R FORWARD “real-world” study.
New results from the HARMONEE Japan/US registration trial, which were presented yesterday at the 2017 Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October – 2 November, Denver, USA), show that the overall incidence of target vessel failure at one year was 7% (lower the original estimated 9%) for the Combo dual therapy stent (OrbusNeich) vs. 4.2% for Xience (Abbott Vascular). This result meant that Combo met the requirement for non-inferiority (p=0.020).
The CE mark has been awarded to a new-generation of Abbott Vascular’s everolimus-eluting, metallic stent Xience. The Xience Sierra, according to a press release, has a new stent design, a new delivery system, and unique sizes.
Bay Labs, a medical technology company developing an artificial intelligence in cardiovascular imaging, has announced that its chief medical officer Randolph P Martin (Emory University School of Medicine, Atlanta, USA) is to speak at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA).
A team at the Technical University of Munich (TUM) has determined that in the first year after a myocardial infarction, women are subject to a significantly higher mortality risk than men with similar case histories.
The US FDA has approved the expansion of CeloNova’s ongoing clinical trial of its proprietary Cobra PzF nano-coated stent to enable the use of 14-day dual antiplatelet therapy (DAPT) in complex patients (eg. high bleeding risk). The COBRA REDUCE trial is first and only randomised control trial to assess 14-day DAPT after percutaneous coronary intervention (PCI).
A new study indicates that long-term exposure to elevated blood pressure is associated with an increased risk of primary and secondary mitral regurgitation. According to investigators Kazem Rahimi (The George Institute for Global Health, University of Oxford, Oxford, UK) and others, this finding implies that blood pressure control may be important for preventing mitral regurgitation.
Boston Scientific has announced key data will be presented at next week’s Transcatheter Cardiovascular Therapeutics (TCT) meeting (29 October–2 November, Denver, USA). For example, on 2 November, data for the Watchman left atrial appendage closure device will be featured in a late-breaking clinical trial session. It will highlight the five-year outcomes from PREVAIL, a randomised trial examining left atrial appendage closure vs. medical therapy in patients with non-valvular atrial fibrillation.
Claret Medical has announced that it has closed on a series C financing of US$14.5m led by Lightstone Ventures, with participation from existing investors Easton Capital, HealthCor Partners, Incept LLC and Sante Ventures. Claret Medical is the developer of the Sentinel cerebral protection system, the first US FDA-cleared cerebral protection device for transcatheter aortic valve implantation (TAVI).
Micro Interventional has announced that the second successful implantation of its minimally invasive annuloplasty (MIA) technology. The patient was enrolled in the first arm of STTAR (Study of transcatheter tricuspid annular repair), which is a clinical trial studying the safety and efficacy of the MIA device. The device is designed to eliminate or greatly reduce tricuspid regurgitation.
Data presented at the 8th Emirates Cardiac Society congress (19–21 October, Dubai, UAE), which is held in collaboration with the American College of Cardiology Middle East Conference, indicate that patients with a history of myocardial infarction are more likely to use emotion-focused coping strategies for stress, such as eating more or drinking alcohol, than patients without a history of myocardial infarction.
Thomas Haldis (Sanford Health, Fargo, USA) and others report in EuroIntervention that interventional cardiologists, as “neurocardiologists”, can be trained to perform mechanical thrombectomy safely and effectively for the management of acute ischaemic stroke. However, they caution that “robust training programmes and stringent quality assurance programmes” need to be in place before the practice can be widely adopted.
Elixir Medical has revealed details of its programme and activities during the 2017 meeting of the transcatheter cardiovascular therapeutics (TCT; 29 October–2 November, Denver, USA). It reports that as part of these activities, it will unveil “a game-changing metallic drug eluting stent platform”.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos